
FDA AEMS E2B(R3) Cutover: 2026 Migration Runbook
A 2026 FDA AEMS E2B(R3) cutover runbook covering the October 1 deadline, applicability, R2 transformation risks, ESG NextGen testing, acknowledgements, validation, and hypercare.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

A 2026 FDA AEMS E2B(R3) cutover runbook covering the October 1 deadline, applicability, R2 transformation risks, ESG NextGen testing, acknowledgements, validation, and hypercare.
© 2026 IntuitionLabs. All rights reserved.